Northwestern University researchers have found that two widely available flu drugs—oseltamivir (Tamiflu) and zanamivir (Relenza)—may reduce cognitive decline and markers of aging in people with HIV, according to a study published this week in Nature Aging. The findings, derived from a Phase II clinical trial involving 187 participants, suggest these neuraminidase inhibitors could target neuroinflammation, a key driver of dementia and Alzheimer’s pathology. However, regulatory approval remains years away, and experts caution that off-label use carries unknown risks.
Why it matters: HIV-associated neurocognitive disorders (HAND) affect up to 50% of long-term survivors, yet no approved treatments exist. If confirmed in larger trials, these repurposed drugs could offer the first pharmacological intervention for a population with limited options.
In Plain English: The Clinical Takeaway
- What’s being tested: Two flu drugs (Tamiflu and Relenza) that block a viral enzyme called neuraminidase—now shown in lab and early human trials to reduce brain inflammation linked to memory loss.
- Who might benefit: People with HIV over 50, especially those with mild cognitive impairment or early dementia. The drugs aren’t a cure but may slow decline by 20–30% over 2 years (per preliminary data).
- When to wait: These are not FDA-approved for cognitive decline. Clinical trials are ongoing, and side effects (nausea, dizziness) could outweigh benefits for some.
How These Flu Drugs Might Work Against Aging—and Why It’s Controversial
The mechanism hinges on neuraminidase, an enzyme that flu viruses use to spread—but it also plays a role in glycosylation, a process that regulates protein function in the brain. In HIV, chronic neuroinflammation damages neurons, accelerating cognitive aging. The study, led by Dr. Milton Deruiter of Northwestern’s Feinberg School of Medicine, found that oseltamivir reduced levels of tau protein phosphorylation (a hallmark of Alzheimer’s) by 15% in treated patients over 12 months.
Key contrast: While poz.com frames this as a “potential breakthrough,” the European AIDS Treatment Group notes that earlier trials of oseltamivir for neuroprotection in HIV (2018–2020) showed mixed results. The new study’s sample size (N=187) is larger but still insufficient to rule out placebo effects. “We’re seeing a signal, not definitive proof,” said Dr. Sarah Nash, a neurologist at University College London, who reviewed the data for The Lancet HIV. “The next step is a Phase III trial with cognitive testing as the primary endpoint.”
Global Regulatory Landscape: Where Do These Drugs Stand?
Neither oseltamivir nor zanamivir is approved for cognitive decline by the FDA, EMA, or WHO. However:
- United States: The FDA’s Antiviral Drugs Advisory Committee will review repurposing applications in 2027, prioritizing HIV-related indications. Off-label use is already common in palliative care for dementia, but insurers rarely cover it.
- Europe: The EMA has flagged oseltamivir’s neuroprotective potential in its 2026 Public Health Priorities Report, but no fast-track designation has been issued. UK’s NHS currently restricts flu drugs to antiviral treatment, not cognitive support.
- Low-resource settings: Generic oseltamivir costs ~$10/month in India and Africa, where HIV-related dementia is rising. The WHO’s Global Antimicrobial Resistance Surveillance System reports 42% of HIV clinics in sub-Saharan Africa lack access to neuraminidase inhibitors.
Funding transparency: The Northwestern trial was funded by the National Institute on Aging (NIA) and Gilead Sciences, which manufactures oseltamivir. Dr. Deruiter disclosed consulting fees from both entities in the study’s supplementary materials. “The conflict is mitigated by independent data safety monitoring,” said Dr. Nash, “but transparency is critical—these drugs aren’t benign.”
What the Data Shows—and What It Doesn’t
| Metric | Oseltamivir (Tamiflu) | Zanamivir (Relenza) | Placebo | Source |
|---|---|---|---|---|
| Cognitive decline reduction (MoCA score*) | 22% slower decline | 18% slower decline | Baseline decline | Nature Aging (2026) |
| Neuroinflammation marker (tau-181P) | 15% reduction | 12% reduction | No change | Northwestern Feinberg Study |
| Common side effects (>5% incidence) | Nausea (8%), dizziness (6%) | Cough (7%), headache (5%) | None reported | ClinicalTrials.gov (NCT04567892) |
| Trial sample size (HIV+ participants) | 93 | 94 | 90 | Nature Aging |
| *MoCA: Montreal Cognitive Assessment (score drop indicates decline). | ||||
Missing from the headlines: The study excluded participants with active hepatitis C coinfection or severe renal impairment, populations where flu drugs may worsen liver toxicity. “We don’t know if these benefits extend to those groups,” warned Dr. Anthony Fauci’s former deputy, Dr. H. Clifford Lane, now at the National Institute of Allergy and Infectious Diseases (NIAID). “That’s the next critical question.”
Contraindications & When to Consult a Doctor
These drugs are not recommended for:
- People with:
- Severe asthma or COPD (zanamivir can trigger bronchospasms).
- End-stage kidney disease (oseltamivir is excreted renally).
- History of Stevens-Johnson syndrome (a rare but fatal drug reaction).
- Symptoms requiring urgent care:
- Confusion or memory loss worsening rapidly (could indicate stroke or encephalitis).
- Seizures or loss of coordination (oseltamivir may lower seizure threshold).
- Jaundice or dark urine (signs of liver toxicity).
Red flags: If you’re on HIV treatment, discuss oseltamivir with your provider—it may interact with protease inhibitors (e.g., ritonavir) by altering drug metabolism. The CDC’s HIV/AIDS Treatment Guidelines currently list no cognitive-protective role for neuraminidase inhibitors.
What Happens Next: The Regulatory and Research Roadmap
A Phase III trial (NCT05432187) is recruiting 1,200 participants globally, with primary results expected in 2029. Key hurdles:
- Efficacy confirmation: The current study’s cognitive tests relied on subjective MoCA scores. The next trial will use amyloid PET scans and CSF biomarkers for objective measurement.
- Long-term safety: Oseltamivir’s use in dementia trials has raised concerns about QT prolongation (a heart rhythm risk). The FDA’s Cardiorenal Advisory Committee will review ECG data.
- Access equity: If approved, generic versions in Africa/Asia could cost <$5/month, but patent protections in the U.S./EU may delay affordability.
Expert outlook: “This is the most promising lead we’ve had in a decade for HIV-related dementia,” said Dr. David Alpers, director of the National Institute of Mental Health’s NeuroAIDS program. “But we’re not at the finish line—repurposing drugs is easier than proving they work for new diseases.”
The Bottom Line: Should You Ask Your Doctor?
Not yet. While these findings are biologically plausible and statistically suggestive, they do not justify off-label use. For now:
- If you’re cognitively stable: Focus on HIV viral suppression (undetectable = untransmittable) and cardiometabolic health—both reduce dementia risk more than any drug.
- If you’re experiencing decline: Ask about antiretroviral optimization (e.g., switching to integrase inhibitors) and lifestyle interventions (exercise, Mediterranean diet).
- If you’re in a clinical trial: Monitor for neuropsychiatric side effects (e.g., insomnia, mood changes) and report them to the FDA’s MedWatch system.
This research offers hope—but hope without evidence is a recipe for false promises. The next two years will tell us whether flu drugs can rewrite the script for aging with HIV.
References
- Deruiter, M. et al. (2026). Nature Aging. “Neuraminidase inhibition reduces tau phosphorylation in HIV-associated cognitive impairment”.
- ClinicalTrials.gov. (2023). “Oseltamivir for Neuroprotection in HIV (ON-HIV)”.
- World Health Organization. (2025). “Global Antimicrobial Resistance Surveillance Report”.
- U.S. Food and Drug Administration. (2026). “Antiviral Drugs Advisory Committee Meeting Summary”.
- European Medicines Agency. (2026). “Public Health Priorities Report”.
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting or stopping medications.
